Adia Med Fully Repays Related-Party Credit Facility, Strengthening Its Financial Position

Adia Med has eliminated $934,970.94 in related-party debt, leaving only lease obligations.

What the company is saying

Adia Med, Inc. (OTCQB:ADIA) announces the full repayment and discharge of its unsecured revolving line of credit with CEO Larry Powalisz. The company emphasizes that $934,970.94 was repaid in total, covering all principal and accrued interest, with a $500,000 payment on October 7, 2026, and a final $434,970.94 payment on October 9, 2026, which included $74,658.94 in interest. The facility, established June 30, 2024, had been increased to a $1,000,000 commitment at 6% annual interest. The announcement frames this as a simplification of the balance sheet, now limited to ordinary operating leases for its clinic and equipment. Larry Powalisz, as both lender and CEO, is positioned as a supportive insider, stating satisfaction with the timely and full repayment. The company signals future flexibility by noting Powalisz's willingness to consider another credit facility if needed, but confirms no such facility currently exists. The tone is confident and focused on financial discipline, with no exaggerated claims.

What the data suggests

The disclosed figures confirm that Adia Med repaid $934,970.94 to fully settle its unsecured revolving line of credit with the CEO, including $74,658.94 in accrued interest. The repayment was executed in two tranches: $500,000 on October 7, 2026, and $434,970.94 on October 9, 2026. The facility, established June 30, 2024, had grown to a $1,000,000 commitment at 6% per annum. With this liability cleared, the company's only remaining obligations are standard operating leases. The announcement does not provide revenue, operating profit, or lease payment figures, but does state that revenue streams include Adia Med clinics, Adia Labs product sales, an 18% equity stake in Cement Factory LLC, and ADIA Life LLC's wellness product distribution. The data is complete for the credit facility event, with no evidence of missed obligations or financial distress. There is no indication of new debt or immediate capital needs.

Analysis

The announcement is factual and proportionate, focusing on the full repayment and discharge of a $934,970.94 unsecured revolving line of credit, with all principal and accrued interest paid as of October 9, 2026. The language is positive but not exaggerated, with no forward-looking claims except a non-committal statement about the CEO's willingness to consider a future credit facility if needed. The bulk of the content is realised and supported by specific numerical disclosures (dates, amounts, interest rates). There is no evidence of narrative inflation or overstatement; the tone matches the event's significance. No large capital outlay or long-dated, uncertain returns are discussed. The only minor gap is the absence of revenue or profitability figures for the company's business lines, but this is not the focus of the release.

Risk flags

• ●The company's recent reliance on a related-party credit facility from its CEO highlights a potential concentration of funding risk. If external capital becomes necessary, dependence on insider financing may limit options or negotiating leverage.
• ●With only ordinary operating leases remaining, the company's short-term obligations appear manageable, but the absence of disclosed revenue or cash flow figures prevents assessment of ongoing liquidity or coverage ratios.
• ●Future capital needs are acknowledged, but no replacement facility is in place. If business conditions change or growth requires new funding, the absence of pre-arranged credit could delay response or force less favorable terms.

Bottom line

Adia Med, Inc. has fully repaid $934,970.94 in related-party debt to its CEO, removing a significant liability and leaving only routine lease obligations. The repayment was completed in two payments within a week, including all accrued interest, and the facility is now fully discharged. This move simplifies the company's financial structure and reduces interest expense, but the announcement does not provide detail on current revenue, cash flow, or lease costs. While the CEO's willingness to provide future credit offers some flexibility, no new facility is currently available. Investors should see this as a positive step for balance sheet clarity, but will need additional financial disclosures to assess ongoing business strength. The key takeaway is that Adia Med has eliminated a major debt, but its future funding options remain open and uncommitted.

Announcement summary

(OTCQB:ADIA) Adia Med, Inc. announced the full repayment and discharge of its unsecured revolving line of credit with Larry Powalisz, the Company's Chief Executive Officer. The total amount repaid was $934,970.94, which included all outstanding principal and accrued interest. On October 7, 2026, the company paid $500,000 toward the facility, followed by a final payment of $434,970.94 on October 9, 2026. The final payment included $74,658.94 of accrued interest. The credit facility was originally established on June 30, 2024, and had been increased to a $1,000,000 commitment, carrying interest at 6% per annum. Larry Powalisz confirmed that the facility was fully satisfied and discharged as of October 9, 2026. With this repayment, the company's remaining obligations are limited to ordinary operating leases, specifically the lease for its clinic in Winter Park Florida and one medical equipment lease. Larry Powalisz, Chief Executive Officer, stated that the company is pleased to have retired the facility and simplified its balance sheet, and that all obligations were met in full and on time. If additional capital is needed in the future, Mr. Powalisz has indicated a willingness to consider providing a new line of credit, though no such facility is currently in place. Additional details are available in the company's Current Report on Form 8-K filed with the Securities and Exchange Commission. Adia Med Inc. generates revenue through its Adia Med clinics, which provide stem cell therapies, platelet-rich plasma (PRP), therapeutic plasma exchange (TPE), and autologous hematopoietic stem cell transplantation (aHSCT), supported by multiple Institutional Review Board (IRB)-approved clinical studies. The company also generates revenue from its Adia Labs division, which manufactures regenerative products (AdiaVita, AdiaLink) for both internal and external providers. Additional revenue streams include an 18% equity stake in Cement Factory LLC and wellness product distribution through ADIA Life LLC.

Disagree with this article?